Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGM - Nasdaq Real Time Price USD

Axsome Therapeutics, Inc. (AXSM)

Compare
111.67
-4.96
(-4.25%)
At close: April 1 at 4:00:02 PM EDT
111.61
-0.06
(-0.05%)
Pre-Market: 4:27:25 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
385,693
385,693
270,600
50,037
--
Cost of Revenue
33,303
33,303
26,065
5,198
--
Gross Profit
352,390
352,390
244,535
44,839
--
Operating Expense
604,828
604,828
427,442
221,340
124,707
Operating Income
-252,438
-252,438
-182,907
-176,501
-124,707
Net Non Operating Interest Income Expense
-6,569
-6,569
-6,453
-7,335
-5,696
Other Income Expense
-28,124
-28,124
-48,918
-3,298
--
Pretax Income
-287,131
-287,131
-238,278
-187,134
-130,403
Tax Provision
85
85
960
--
--
Net Income Common Stockholders
-287,216
-287,216
-239,238
-187,134
-130,403
Diluted NI Available to Com Stockholders
-287,216
-287,216
-239,238
-187,134
-130,403
Basic EPS
-6.58
-5.99
-5.27
-4.60
-3.47
Diluted EPS
-6.58
-5.99
-5.27
-4.60
-3.47
Basic Average Shares
47,615.31
47,914.25
45,425.21
40,655.94
37,618.60
Diluted Average Shares
47,615.31
47,914.25
45,425.21
40,655.94
37,618.60
Total Operating Income as Reported
-280,562
-280,562
-231,825
-179,799
-124,707
Total Expenses
638,131
638,131
453,507
226,538
124,707
Net Income from Continuing & Discontinued Operation
-287,216
-287,216
-239,238
-187,134
-130,403
Normalized Income
-259,092
-259,092
-200,592.78
-183,836
-130,403
Interest Expense
6,569
6,569
6,453
7,335
5,696
Net Interest Income
-6,569
-6,569
-6,453
-7,335
-5,696
EBIT
-280,562
-280,562
-231,825
-179,799
-124,707
EBITDA
-272,604
-272,604
-224,991
-175,397
-124,631
Reconciled Cost of Revenue
31,737
31,737
25,606
4,935
--
Reconciled Depreciation
7,958
7,958
6,834
4,402
76
Net Income from Continuing Operation Net Minority Interest
-287,216
-287,216
-239,238
-187,134
-130,403
Total Unusual Items Excluding Goodwill
-28,124
-28,124
-48,918
-3,298
--
Total Unusual Items
-28,124
-28,124
-48,918
-3,298
--
Normalized EBITDA
-244,480
-244,480
-176,073
-172,099
-124,631
Tax Rate for Calcs
--
--
0
--
--
Tax Effect of Unusual Items
--
--
-10,272.78
--
--
12/31/2021 - 11/19/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TGTX TG Therapeutics, Inc.
37.75
-4.26%
 
MDGL Madrigal Pharmaceuticals, Inc.
323.98
-2.19%
 
VKTX Viking Therapeutics, Inc.
23.91
-0.99%
 
SWTX SpringWorks Therapeutics, Inc.
41.88
-5.10%
 
BHVN Biohaven Ltd.
22.60
-5.99%
 
VRNA Verona Pharma plc
58.54
-7.80%
 
WVE Wave Life Sciences Ltd.
7.74
-4.21%
 
APLS Apellis Pharmaceuticals, Inc.
22.68
+3.70%
 
IOVA Iovance Biotherapeutics, Inc.
3.2500
-2.40%
 
BBIO BridgeBio Pharma, Inc.
33.02
-4.48%